Results 211 to 220 of about 548,432 (354)
This study reveals that the Fgl2‐FcγRIIB signaling axis is a key mechanism by which MDSCs mediate tumor immune evasion. Tumor‐derived exosomes systemically activate MDSCs via this pathway, positioning this axis as a promising broad‐spectrum target for cancer immunotherapy.
Fenglin Lin +12 more
wiley +1 more source
Corilagin induces pyroptosis in AML cells by activating the TXNIP-caspase-3-GSDME pathway. [PDF]
Feng G +17 more
europepmc +1 more source
Vorinostat Potentiates Chemoimmunotherapy in Immune‐Enriched Pancreatic Cancer
Immune‐enriched pancreatic cancer does not confer a significant survival advantage. SAHA sensitizes these “hot” tumors to chemoimmunotherapy by disrupting a FASN/PARP9‐driven “metabolic trap” and enhancing CD8+ T cell function. A CD8high/FASNhigh/PARP9high signature identifies patients who are most likely to benefit from the “gemcitabine‐nivolumab‐SAHA”
Chen Chen +13 more
wiley +1 more source
Emestrin-Type Epidithiodiketopiperazines Inhibited Gasdermin D-Mediated Pyroptosis via Caspase-3/7 Activation. [PDF]
Geng B +16 more
europepmc +1 more source
Tumor dsDNA released by cryoablation is taken up by macrophages, activating the cGAS‐STING signaling pathway. This leads to an expansion of the CXCL10+ macrophage pool and increased secretion of CXCL10, which in turn recruits CXCR3+ T cells from draining lymph nodes into the tumor microenvironment to exert anti‐tumor effects.
Xinxin Zhi +17 more
wiley +1 more source
Gastric cancer‐derived exosomal TAGLN2 is identified as a key mediator of vascular reprogramming, with significantly elevated levels detected in patient serum. Independent of canonical SEMA4D signaling, it nucleates a cytoplasmic TAGLN2/NRP1/SEMA4D ternary complex that dually activates YAP, promoting angiogenesis, vascular dysfunction, and metastasis ...
Shuqi Yu +7 more
wiley +1 more source
IKBKE downregulation increases chemosensitivity through pyroptosis mediated by the caspase-3/GSDME pathway in pancreatic cancer. [PDF]
Ren T, Chen X, Wang X, Xu Y, Shao N.
europepmc +1 more source

